ConductScience.org, home

Paper40495487

Auranofin, an antirheumatic drug, shows anticancer stem cell potential via suppression of the Stat3 signal.

Ko SY and 7 others. BMB Rep, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Auranofin, an antirheumatic drug, shows anticancer stem cell potential via suppression of the Stat3 signal. Papers, record 40495487. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40495487

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Auranofin, an antirheumatic drug, shows anticancer stem cell potential via suppression of the Stat3 signal.
PubMed
Journal
BMB Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2025-08-20
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ko SYSeung-Yeon
2Kim YYuna
3Chung JSJin Sun
4Kim YBYoung Bin
5Kim SLSu-Lim
6Lee DSDong-Sun
7Chun KHKyung-Hee
8Choi HSHack Sun

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antirheumatic AgentsMajor topic
AuranofinMajor topic
Neoplastic Stem CellsMajor topic
STAT3 Transcription FactorMajor topic
Female
Humans
Antineoplastic Agents
Apoptosis
Breast Neoplasms
Cell Line, Tumor
Cell Movement
Cell Proliferation
Interleukin-8
MCF-7 Cells
Signal Transduction

Source PubMed

Download CSV of topics

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118277610Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages.Arch Pharm Res2008https://conductscience.org/library/papers/18277610PubMed
230827998Potential Anticancer Activity of Auranofin.Chem Pharm Bull (Tokyo)2019https://conductscience.org/library/papers/30827998PubMed
335201489The gold complex auranofin: new perspectives for cancer therapy.Discov Oncol2021https://conductscience.org/library/papers/35201489PubMed
432522692STAT3: A key signaling molecule for converting cold to hot tumors.Cancer Lett2020https://conductscience.org/library/papers/32522692PubMed
535078017Thioredoxin reductase: An emerging pharmacologic target for radiosensitization of cancer.Transl Oncol2022https://conductscience.org/library/papers/35078017PubMed
628664387Overview of Cancer Stem Cells and Stemness for Community Oncologists.Target Oncol2017https://conductscience.org/library/papers/28664387PubMed
719760641Cancer stem cells: cell culture, markers, and targets for new therapies.J Cell Biochem2009https://conductscience.org/library/papers/19760641PubMed
834905391Understanding breast cancer as a global health concern.Br J Radiol2022https://conductscience.org/library/papers/34905391PubMed
936831661Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/36831661PubMed
1035096183Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis.Cell Mol Bioeng2022https://conductscience.org/library/papers/35096183PubMed
1124032691Targeting IL-8 signalling to inhibit breast cancer stem cell activity.Expert Opin Ther Targets2013https://conductscience.org/library/papers/24032691PubMed
1233327542Breast Cancer Stem Cells: Biomarkers, Identification and Isolation Methods, Regulating Mechanisms, Cellular Origin, and Beyond.Cancers (Basel)2020https://conductscience.org/library/papers/33327542PubMed
1334731781Auranofin: Past to Present, and repurposing.Int Immunopharmacol2021https://conductscience.org/library/papers/34731781PubMed
1424041156Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.Breast Cancer Res2013https://conductscience.org/library/papers/24041156PubMed
1536915147Paracrine secretion of IL8 by breast cancer stem cells promotes therapeutic resistance and metastasis of the bulk tumor cells.Cell Commun Signal2023https://conductscience.org/library/papers/36915147PubMed
1633584277The Breast Cancer Stem Cells Traits and Drug Resistance.Front Pharmacol2020https://conductscience.org/library/papers/33584277PubMed
1734445421Physalin A, 13,14-Seco-16, 24-Cyclo-Steroid, Inhibits Stemness of Breast Cancer Cells by Regulation of Hedgehog Signaling Pathway and Yes-Associated Protein 1 (YAP1).Int J Mol Sci2021https://conductscience.org/library/papers/34445421PubMed
1836120232Evaluation of CD44+/CD24- and Aldehyde Dehydrogenase Enzyme Markers in Cancer Stem Cells as Prognostic Indicators for Triple-Negative Breast Cancer.Cureus2022https://conductscience.org/library/papers/36120232PubMed
1936860815Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities.Mol Ther Oncolytics2023https://conductscience.org/library/papers/36860815PubMed
2029874570JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance.Cell Metab2018https://conductscience.org/library/papers/29874570PubMed

See all 40 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42209569Evaluation of cytotoxic and cellular effects of zinc nanoparticles from Saccharum officinarum (Jaggery) extract on breast cancer cells.Sci Rep2026https://conductscience.org/library/papers/42209569PubMed
42157933Nuclear Galectin-1 Drives Cancer Progression through O-GlcNAcylation-Dependent Regulation of SOX2.Int J Biol Sci2026https://conductscience.org/library/papers/42157933PubMed
40834985Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis.Cancer Lett2025https://conductscience.org/library/papers/40834985PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CXCL83576PubTator's text mininghttps://conductscience.org/library/genes/3576NCBI Gene
STAT36774PubTator's text mininghttps://conductscience.org/library/genes/6774NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40495487

GET https://conductscience.org/api/papers/v1/40495487/references?page=2